Floatz logo

Recombinant Interleukin-12

Melanoma (Skin)

National Cancer Institute (NCI)protein_peptidePhase 2Dormant
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
81/ 100

Competitive context

152 Active assets in the Melanoma (Skin) cohort.

Asset / SponsorPhaseRating
Alpha-Interferon
MIPO Clinic
Phase 3BBB
CIS-DIAMMINEDICHLOROPLATINUM II
MIPO Clinic
Phase 3BBB
DACARBAZINE
Linnaeus Therapeutics, Inc.
Phase 3BBB
Tyrosinase Peptide
University of Southern California
Phase 3BBB
TIL
City of Hope Medical Center
Phase 2BBB

View all 50 →

Same molecule, other indications

Recombinant Interleukin-12 is also rated in:

primary cutaneous T-cell non-Hodgkin lymphomaDormant
BB
Indicative ·
64 / 100
View asset →
mycosis fungoidesDormant
BB
Indicative ·
64 / 100
View asset →
primary peritoneal carcinomaDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →